KNI-272

Drugs of the Future

Volumn 21, Issue 10, 1996, Pages 1022-1027

  Ireland, C D ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; KYNOSTATIN 272; PROTEINASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; DOG; DRUG BLOOD LEVEL; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; SHORT SURVEY; VIRUS INFECTION;

EID: 0029904523     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.10.375535     Document Type: Short Survey

References (41)

1. Mimoto, T., Kisanuki, S., Takahasihi, O., Kiso, Y. (Nikko Kyodo Co., Ltd.). Process for producing peptide derivs. and salts thereof. EP 574135.
2. Kiso, Y. Design and synthesis of HIV protease inhibitors containing allophenylorstatine as a transition-state mimic. Adv Exp Med Biol 1995, 362(Aspartic Proteinases): 413-23.
3. Maeda, S., Moriwaki, H. (Japan Energy Co., Ltd.; Hamari Yakuhin). Manufacturing method for peptide derivs. and their salts. JP 94220031.
4. Kimura, T., Ohtake, J., Nakata, S., Enomoto, H., Moriwaki, H., Akaji, K., Kiso, Y. Synthesis and prodrugs of HIV protease inhibitors. Peptide Chem 1994, 157-60.
5. Mimoto, T., Imai, J., Tanaka, S. et al. Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic. Chem Pharm Bull 1991, 39: 2465-7.
6. Mimoto, T., Imai, J., Tanaka, S., Hattori, N., Kisanuki, S., Akaji, K., Kiso, Y. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem Pharm Bull 1991, 39: 3088-90.
7. Mimoto, T., Imai, J., Kisanuki, S., Enomoto, H., Hattori, N., Akaji, K., Kiso, Y. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: Conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine. Chem Pharm Bull 1992, 40(8): 2251-3.
8. Kageyama, S., Mimoto, T., Murakawa, Y. et al. In vitro anti-human immunodeficiency virus (HIV) activites of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob Agents Chemother 1993, 37: 810-7.
9. Tanaka, M., Mimoto, T., Anderson, B., Gulnik, S., Bhat, T.N., Yusa, K., Hayashi, H., Kiso, Y., Erickson, J.W., Mitsuya, H. Identification of protease inhibitors containing allophenylnorstatine active against both wild-type and KNI-272-resistant HIV-1 variants. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Tu.A.260.
10. Kiso, Y., Kimura, T., Otake, J., Nakata, S., Enomoto, H., Moriwaki, H., Nakatani, M., Akaji, K. "O→ N intramolecular acyl migration"-type prodrugs of tripeptide inhibitors of HIV protease. 14th Amer Peptide Symp (June 18-23, Columbus) 1995, Abst L009.
11. Baldwin, E.T., Bhat, T.N., Gulnik, S., Liu, B., Topol, I.A., Kiso, Y., Mimoto, T., Mitsuya, H., Erickson, J. W. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure 1995, 3: 581-90.
12. Kiso, Y., Mimoto, T., Kato, R., Mitoguchi, T., Nakata, S., Kimura, T., Ussery, M.A. Allophenylnorstatine-containing peptidomimetic HIV protease inhibitors exhibit both in vitro and in vivo antiviral activities. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Mo.A.1060.
13. Ussery, M.A., Wood, O., Broud, D., Bacho, M., Kunder, S., Papermaster, S., Kiso, Y., Black, P. The protease inhibitor KNI-272 inhibits HIV-1 infection in vivo in the HuPBMC-SCID mouse model. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Tu.A.262.
14. Ussery, M.A., Wood, O.L., Broud, D., Bacho, M., Kunder, S.C., Papermaster, S., Kiso, Y., Black, P.L. Antiviral activity of the protease inhibitor KNI-272 in vivo in the HIV-infected HuPBMC-SCID mouse model. Antivir Res 1996, 30(1): Abst 6.
15. Anderson, B., Kageyama, S., Ueno, T., Shirasaka, T., Liu, B., Gulnick, S., Erickson, J., Mitsuya, H. In vitro induction of HIV-1 with reduced sensitivity to HIV protease inhibitors, KNI-227 and KNI-272. 2nd Natl Conf Hum Retroviruses Relat Infect (Jan 29-Feb 2, Washington DC) 1995, Abst 95.
16. Kiriyama, A., Fujita, K., Takemura, S., Kuramoto, H., Kiso, Y., Takada, K. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration. Biopharm Drug Dispos 1994, 15: 617-26.
17. Sugahara, M., Kiriyama, A., Hamada, Y., Kiso, Y., Takada, K. Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: Effects of solvent. Biopharm Drug Dispos 1995, 16: 269-77.
18. Kiriyama, A., Sugahara, M., Yoshikawa, Y., Kiso, Y., Takada, K. The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs. Biopharm Drug Dispos 1996, 17: 125-34.
19. Placke, M.E., Emmerling, D.C., Lynch, M.E., Graves, S.W., Tosca, P.J., Yarrington, J.T., Tomaszewski, J.E. Toxicity of protease inhibitor KNI-272 in rats and dogs following continuous intravenous infusion or repeated IV treatment. Proc Amer Assoc Cancer Res 1994, 35: Abst 2751.
20. Humphrey, R.W., Nguyen, B.-Y., Wyvill, K.M., Shay, L.E., Lietzau, J., Ueno, T., Fukasawa, T., Hayashi, H., Mitsuya, H., Yarchoan, R. A phase I trial of HIV protease inhibitor KNI-272 in patients with AIDS or symptomatic HIV infection. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Mo.B.1132.
21. Yamada, A., Anderson, B., Kageyama, S., Erickson, J., Ueno, T, Hayashi, H., Mitsuya, H. Detection of mutations conferring on HIV-1 drug resistance in patients receiving KNI-272. 11th Int Conf AIDS (July 7-12, Vancouver) 1996, Abst Th.B.4346.
22. Japan Energy has begun clinical trials on anti-AIDS agent in England. Nikkei Sangyo Shinbun 1995, December 5.
23. Chokekijchai, S., Shirasaka, T., Weinstein, J.N., Mitsuya, H. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: Implications for its combined use with AZT or ddl. Antivir Res 1995, 28: 25-38.
24. Kageyama, S., Anderson, B.D., Hoesterey, B.L., Hayashi, H., Kiso, Y., Flora, K.P., Mitsuya, H. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob Agents Chemother 1994, 38: 1107-11.
25. Kirayama, A., Mimoto, T., Kisanuki, S., Kiso, Y., Takada, K. Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations. Biopharm Drug Dispos 1993, 14: 697-707.
26. Humphrey, R.W., Mitsuya, H., Yarchoan, R. HIV protease inhibitors do not prevent cell death during single-cycle HIV infection of CEM-ss cells in vitro. 2nd Natl Conf Hum Retroviruses Relat Infect (Jan 29-Feb 2, Washington DC) 1995, Abst 92.
27. Kiso, Y., Mimoto, T., Imai, J., Kisanuki, S., Hattori, N., Enomoto, H., Akaji, K., Kageyama, S., Mitsuya, H. Design of HIV protease inhibitors with effective antiviral activity: Use of allophenylnorstatine as a transition-state mimic. In: Peptides 1992, C.H. Schneider and A.N. Eberle (Eds.), ESCOM Science Publishers B.V., Netherlands, 1993, 805-7.
28. Kiso, Y. Design of HIV protease inhibitors based on the transition state concept. Pept Biol Chem Proc Chin Pept Symp 1992, 1993: 87-92.
29. Baldwin, E.T., Bhat, T.N., Gulnik, S., Liu, B., Kiso, Y., Mitsuya, H., Erickson, J.W. Structure of HIV-1 protease with KNI-272: A transition state mimetic inhibitor containing allophenylnorstatine. Adv Exp Med Biol 1995, 362(Aspartic Proteinases): 445-9.
30. Kiso, Y., Mimoto, T., Imai, J., Kisanuki, S., Enomoto, H., Hattori, N., Takada, K., Akaji, K., Kageyama, S., Mitsuya, H. The promising anti-HIV agent kynostatin (KNI)-272: A highly selective and superactive HIV protease inhibitor containing allophenylnorstatine. Pept Chem Struct Biol Proc Amer Pept Symp 1993, 1994: 619-21.
31. Mimoto, T., Imai, J., Kisanuki, S., Hattori, N., Takahashi, O., Enomoto, H., Akaji, K., Kiso, Y. Structure-activity relationships of HIV protease inhibitors containing hydroxymethylcarbonyl isostere as a transition state mimic. In: Peptides 1992, C.H. Schneider and A.N. Eberle (Eds.), ESCOM Science Publishers B.V., Netherlands, 1993, 631-2.
32. Enomoto, H., Mimoto, T., Kisanuki, S., Kimura, T., Hattori, N., Kageyama, S., Mitsuya, H., Akaji, K., Kiso, Y. Structure-activity relationships of tripeptide HIV protease inhibitors containing the hydroxymethylcarbonyl isostere. In: Peptide Chemistry 1993, Y. Okada (Ed.), Protein Research Foundation, 1994, 181-4.
33. Mimoto, T., Kisanuki, S., Imai, J., Enomoto, H., Hattori, N., Kageyama, S., Mitsuya, H., Akaji, K., Kiso, Y. Design and activity of protease active site-targeted anti-HIV agents containing allophenylnorstatin. Pept Chem 1992, 1993: 544-6.
34. Gulnik, S.V., Sovorov, L.I., Liu, B., Yu, B., Anderson, B., Mitsuya, H., Erickson, J.W. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995, 34: 9282-7.
35. Kiso, Y., Mimoto, T., Hattori, N. et al. KNI-272, a potent HIV protease inhibitor, as a potential anti-HIV drug for oral administration. 9th Int Conf AIDS/4th STD World Cong (June 6-11, Berlin) 1993, Abst PO-A25-0567.
36. Anderson, B., Kageyama, S., Ueno, T., Mitsuya, H. In vitro induction of HIV-1 with reduced sensitivity to HIV protease inhibitors, KNI-227 and KNI-272. 10th Int Conf AIDS/Int Conf STD (Aug 7-12, Yokohama) 1994, Abst 516B.
37. Fukazawa, T., Takeuchi, N., Fujisawa, N. et al. KNI-272: A potent HIV protease inhibitor exhibiting a favorable oral bioavailability in beagle dogs. 10th Int Conf AIDS/Int Conf STD (Aug 7-12, Yokohama) 1994, Abst PB0841.
38. Kiso, Y., Mimoto, T., Enomoto, H., Kisanuki, S., Moriwaki, H., Kimura, T., Hattori, N., Hayashi, H., Takada, K., Akaji, K. Kynostatin (KNI)-272: An orally bioavailable tripeptide HIV protease inhibitor containing allophenylnorstatine. 10th Int Conf AIDS/Int Conf STD (Aug 7-12, Yokohama) 1994, Abst PA0299.
39. Anderson, B.D., Kageyama, S., Ueno, T., Mitsuya, H. In vitro induction and characterization of HIV-1 with reduced sensitivity to HIV protease inhibitors, KNI-227 and KNI-2272. Clin Res 1994, 42(2): 281A.
40. Ussery, M.A., Wood, O.L., Broud, D.D., Kunder, S.C., Papermaster, S., Kiso, Y., Black, P.L. In vivo antiviral activity of the protease inhibitor KNI-272 in the HIV-infected HuPBMC-SCID mouse model. 35th Intersci Conf Antimicrob Agents Chemother (Sept 17-20, San Francisco) 1995, Abst 1125.
41. Kiso, Y., Mimoto, T., Kimura, T. et al. An orally available, highly selective and superpotent HIV protease inhibitor using the excellent hydroxymethylcarbonyl isostere as a transition-state mimic. AFMC Int Med Chem Symp (Sept 3-8, Tokyo) 1995, Abst P7T152 SC62.